Id: | acc1340 |
Group: | 2sens |
Protein: | mTOR |
Gene Symbol: | MTOR |
Protein Id: | P42345 |
Protein Name: | MTOR_HUMAN |
PTM: | phosphorylation |
Site: | Ser2448 |
Site Sequence: | NKRSRTRTDSYSAGQSVEILD |
Disease Category: | Cancer |
Disease: | Breast Cancer |
Disease Subtype: | |
Disease Cellline: | MCF7 |
Disease Info: | |
Drug: | rapamycin |
Drug Info: | "Rapamycin is a macrolide immunosuppressant and antiproliferative drug used primarily to prevent organ transplant rejection and in cancer therapy, requiring regular monitoring of blood drug concentrations due to its narrow therapeutic index." |
Effect: | modulate |
Effect Info: | Rapamycin reduces mTOR phosphorylation. |
Note: | no tumor effct |
Score: | 3.0 |
Pubmed(PMID): | 30154572 |
Sentence Index: | 30154572_6-7 |
Sentence: | "Since altered expression of protein kinase B (PKB)/Akt in breast cancer cells affect N-myristoyltransferase 1 (NMT1) expression and activity, we investigated whether mTOR, a downstream target of PKB/Akt, regulates NMT1 in ER positive breast cancer cells (MCF7 cells). We inhibited mTOR by treating MCF7 cells with rapamycin and observed that the expression of NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation." |
Sequence & Structure:
MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
MTOR | PERHEXILINE | Serine/threonine-protein kinase mTOR inhibitor | 4 | - | cardiovascular disease | ATC |
MTOR | PERHEXILINE | Serine/threonine-protein kinase mTOR inhibitor | 3 | Withdrawn | hypertrophic cardiomyopathy | ClinicalTrials |
MTOR | DACTOLISIB | Serine/threonine-protein kinase mTOR inhibitor | 3 | Completed | infection | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 3 | - | neoplasm | ATC |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 3 | Completed | soft tissue sarcoma | ClinicalTrials |
MTOR | GEDATOLISIB | Serine/threonine-protein kinase mTOR inhibitor | 3 | Recruiting | breast cancer | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 3 | Completed | bone sarcoma | ClinicalTrials |
MTOR | SF-1126 | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | head and neck squamous cell carcinoma | ClinicalTrials |
MTOR | ONATASERTIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | hepatocellular carcinoma | ClinicalTrials |
MTOR | INDOXIMOD | mTORC1 activator | 2 | Completed | metastatic prostate cancer | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | myelodysplastic syndrome | ClinicalTrials |
MTOR | GEDATOLISIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | myelodysplastic syndrome | ClinicalTrials |
MTOR | GEDATOLISIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | acute myeloid leukemia | ClinicalTrials |
MTOR | SAPANISERTIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Active, not recruiting | T-cell acute lymphoblastic leukemia | ClinicalTrials |
MTOR | VISTUSERTIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Active, not recruiting | adenocarcinoma | ClinicalTrials |
MTOR | VISTUSERTIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | clear cell renal carcinoma | ClinicalTrials |
MTOR | VISTUSERTIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | gastric adenocarcinoma | ClinicalTrials |
MTOR | PERHEXILINE | Serine/threonine-protein kinase mTOR inhibitor | 2 | Terminated | hypertrophic cardiomyopathy | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | leiomyosarcoma | ClinicalTrials |
MTOR | DACTOLISIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Active, not recruiting | infection | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | lymphoma | ClinicalTrials |
MTOR | VOXTALISIB | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | lymphoma | ClinicalTrials |
MTOR | PERHEXILINE | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | hypertrophic cardiomyopathy | ClinicalTrials |
MTOR | PERHEXILINE | Serine/threonine-protein kinase mTOR inhibitor | 2 | Recruiting | hypertrophic cardiomyopathy | ClinicalTrials |
MTOR | RIDAFOROLIMUS | Serine/threonine-protein kinase mTOR inhibitor | 2 | Completed | leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACMTOR-Ser2448 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | 0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 2448 | A | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 22886792 |
S | 2448 | U | Adrenocortical carcinoma | Phosphorylation | 20484036 |
S | 2448 | U | Breast cancer | Phosphorylation | 36797347 |
S | 2448 | U | Cervical squamous cell cancer | Phosphorylation | 19079619 |
S | 2448 | U | Granulomatosis with polyangiitis | Phosphorylation | 37720230 |
S | 2448 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
S | 2448 | U | Ovarian cancer | Phosphorylation | 15208673 |
S | 2448 | U | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 21474066 |
S | 2448 | U | Liver cancer | Phosphorylation | 23537100 |
S | 2448 | U | Non-small cell lung cancer | Phosphorylation | 33523588 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 7.5641 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | BT-474 | Lapatinib | 6.6312 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | BT-474 | Pertuzumab | -1.5374 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | BT-474 | Trastuzumab | -1.8853 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | BT-474 | Trastuzumab | -2.8992 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | HeLa | A485 | 9.9669 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | HeLa | A485 | 6.4419 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | HeLa | A486 | 5.2648 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | HeLa | A486 | 5.2308 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | HeLa | A486 | 5.2273 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 9.2779 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 9.2546 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 9.2353 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | K562 | Dasatinib | 8.9987 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | K562 | Dasatinib | 7.7586 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | BT-474 | Lapatinib | 6.9171 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 10.7673 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Dasatinib | 8.7783 | - | |
P42345 | MTOR | P | Ser2448;Ser2454 | TRTDS(ph)YSAGQS(ph)VEILDGVELGEPAHKK | K562 | Imatinib | 8.2056 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | K562 | Imatinib | 5.4862 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | KYSE-520 | SHP099 | 10.0734 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | KYSE-520 | SHP099 | 5.8963 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | KYSE-520 | SHP099 | 5.8317 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | PC-9 | AZD4547 | 9.2645 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | PC-9 | AZD4547 | 7.8622 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | PC-9 | GeftinibAZD4547-1to80 | 9.3258 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | PC-9 | GeftinibAZD4547-1to80 | 8.1698 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | PC-9 | GeftinibAZD4547-1to80 | 6.2543 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | SK-BR-3 | Lapatinib | 7.7904 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | SK-BR-3 | Trastuzumab | -2.0623 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 7.2614 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Afatinib | 7.8778 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Afatinib | 7.408 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Afatinib | 8.2218 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Afatinib | 7.6372 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Afatinib | 7.7982 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Dasatinib | 10.6207 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 6.7138 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 5.4223 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 5.3723 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Dasatinib | 2 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Dasatinib | 9.8622 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 6.6761 | - | |
P42345 | MTOR | P | Ser2448;Ser2454 | TDS(ph)YSAGQS(ph)VEILDGVELGEPAHK | A431 | Dasatinib | 6.0055 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 2.0001 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Afatinib | 12.0893 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 8.9829 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Dasatinib | 8.5089 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 7.0119 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 6.3584 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Gefitinib | 9.1286 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 7.9143 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 6.013 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 5.4977 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Gefitinib | 8.5642 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 8.1262 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Gefitinib | 7.2534 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Imatinib | 16.5229 | - | |
P42345 | MTOR | P | Ser2448 | TRTDS(ph)YSAGQSVEILDGVELGEPAHK | A431 | Imatinib | 13.7382 | - | |
P42345 | MTOR | P | Ser2448 | TDS(ph)YSAGQSVEILDGVELGEPAHKK | A431 | Imatinib | 6.5676 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.